This article is part of a special series investigating the GLP-1 agonist boom. Read more here. A growing number of studies show that semaglutide seems to have many beneficial effects in addition ...

This article is part of a special series investigating the GLP-1 agonist boom. Read more here. Among the comments, however, you will frequently find reports of other – wholly unexpected ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

He also has mild, untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about possible pancreatitis due to his alcohol consumption.

After about a year of limited progress, Makowicki’s physician recommended she start on Mounjaro, a glucagon-like peptide-1 agonist, commonly known as a GLP-1. The results were unlike anything ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the ...

This Texas-based company thinks so. ChipMonk Baking has been in the game of making healthier cookies since long before GLP-1 agonist weight-loss drugs like Ozempic and Wegovy took the U.S. by storm.

He also has mild, untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about possible pancreatitis due to his alcohol consumption.

an oral GLP-1R agonist, shows potential in obesity treatment, with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...